Illuminant Surgical Secures $8.4M in Seed Funding to Advance Real-Time Surgical Visualization Technology
Illuminant Surgical just raised $8.4M in Seed funding, and somewhere in Los Angeles a projector got promoted from “nice to have” to “I can literally see through you.” Not in a sci-fi, Black Mirror way. In a “surgeon finally doesn’t have to guess where the line between precision and prayer sits” kind of way.
Credit where it’s due. Co-Founders and Co-CEOs Eldrick Millares and James Hu, MD didn’t stumble into this lane. Stanford roots, hardware meets medicine, LiDAR logic colliding with operating rooms. You don’t get to “X-ray vision for the body” by thinking small. You get there by asking why surgeons are still translating flat screens into 3D consequences like it’s 1998.
Wing 2 Wing Ventures led the round, with Elderberry Ventures, Soma Capital, and DRF riding shotgun. And then there’s the quiet muscle in the cap table. NSF, National Cancer Institute, National Institute on Aging. Non-dilutive capital that doesn’t just believe, it validates. About 50% of the round backed by institutions that don’t chase hype cycles. They fund what actually has to work.
The product is called Skylight, which is either precise or perfectly literal depending on how you look at it. Real time anatomical projection directly onto the patient. No headset. No mental gymnastics. No “look left at the monitor, then right at reality” dance. Just information where the hands are. Where the decision lives. Where milliseconds matter more than opinions.
They are building this inside a 12,000+ sq ft Los Angeles facility with R&D, pilot manufacturing, and a BSL-2 cadaver lab under one roof. Translation. Feedback loops get tight. Engineers don’t theorize, they iterate. Clinicians don’t wait, they respond. That’s how you compress years into quarters without breaking the science.
There’s a bigger play hiding in plain sight. Over 11M procedures across spine, pain, and interventional radiology in the U.S. alone. Most of them still rely on fragmented visualization. Screens over here. Anatomy over there. Experience filling the gap. Illuminant Surgical is betting that gap is where the next generation of outcomes gets decided.
And here’s the part founders should sit with for a second. This didn’t happen because the story sounded good. It happened because the system fits into existing workflows, reduces cognitive load, and respects the reality of a procedure room. No ego in the product. Just utility. Investors can smell that from a mile away.
It’s early. Not FDA cleared. Not commercially available. But the direction is loud. When you stop asking doctors to translate and start letting them see, you don’t just improve a tool. You change the conversation inside the room where it all counts.
